Business
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal third quarter ended March 31, 2025.
About this update from Palatin Technologies, Inc.
[{"type":"text","content":"Significant Progress in Obesity and Ocular Programs","length":51,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Teleconference and Webcast to be held today - May 14, 2025, at 11:00 AM EST","length":75,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":75,"olType":false},{"type":"text","content":"CRANBURY, N.J., May 14, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal third quarter ended March 31, 2025.","length":321,"tagName":"p"},{"type":"image","alt":"Palatin Technologies, Inc.","displaySize":"","headline":null,"caption":"Palatin Technologies, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":345,"url":"https://media.zenfs.com/en/prnewswire.com/965a03f88317259fbf5e1a6eed8134bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AQfwD723Z4IUxlX8GukUvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYwODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/965a03f88317259fbf5e1a6eed8134bc","width":400,"height":345}},"href":"https://mma.prnewswire.com/media/464561/Palatin_Technologies_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We had a strong quarter operationally, with significant progress across both our obesity and ocular pipelines," said Carl Spana, Ph.D., President and CEO of Palatin. "Our obesity program Phase 2 study results demonstrated the synergistic potential of melanocortin receptor modulation with GLP-1-based therapies, and our PL9643 Phase 3 dry eye disease program results showed a level of symptom resolution not previously achieved by any approved treatments."","length":477,"tagName":"p"},{"type":"text","content":"Obesity Program Highlights","length":26,"tagName":"p"},{"type":"text","content":"Phase 2 Study Co-administration of Bremelanotide (MC4R agonist) + Tirzepatide (GLP-1/GIP dual agonist):","length":108,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Met primary endpoint in the 8-week treatment study with high statistical significance (p<0.0001).","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Patients receiving co-admini...